Theranostic Radiopharmaceuticals : at the Inflection Point
Résumé
There has been a surge of interest in the field of “theranostic” (therapeutic + diagnostic) radiopharmaceuticals,
both clinically and commercially. The potential has arguably been evident for several decades but there have been
some hard-learned lessons and some astonishing failures that have contributed to a lack of traction for the nuclear
medicine industry. There is evidence that this has now changed and recent product development, clinical
outcomes and commercial focus have given the field a much-needed boost. In this article we explore the issues
and opportunities that currently define the field. We take the position that we are at the point where such a cost-effective
and clinically beneficial precision medicine strategy has reached an inflection point on its trajectory
toward success.